Table 2 Interobserver Agreement for LI-RADS Imaging Features of HCCs in Contrast-Enhanced CT and Gadoxetic Acid-Enhanced MRI.

From: Improved diagnosis of histological capsule in hepatocallular carcinoma by using nonenhancing capsule appearance in addition to enhancing capsule appearance in gadoxetic acid-enhanced MRI

Variable

CE-CT

EOB-MRI

Observation size (mm)

0.987 (0.984–0.990)

0.982 (0.977–0.987)

Nonrim APHE

0.690 (0.421–0.959)

0.681 (0505–0.872)

Nonperipheral washout

0.614 (0.490–0.739)

0.692 (0.613–0.771)

TP hypointensity

–

0.605 (0.492–0.719)

Enhancing capsule

0.689 (0.615–0.765)

0.597 (0.508–0.687)

Enhancing/nonenhancing capsule

–

0.667 (0.581–0.752)

  1. Data are expressed as intraclass correlation coefficient (ICC) for observation size and as κ value for nonrim APHE, nonperipheral “washout”, TP hypointensity, enhancing “capsule”, and nonenhancing/enhancing “capsule”.
  2. Data in parentheses are expressed as 95% confident intervals.
  3. CE-CT contrast-enhanced CT, EOB-MRI gadoxetic acid-enhanced MRI, APHE arterial phase hyperenhancement, TP transitional phase.
Back to article page